Coronary Artery Disease (CAD) is primarily caused by Atherosclerosis; which is a buildup of Cholesterol, fats, calcium and waste products (Plaque) inside coronary artery walls. Recently, FLOWPROMOTE trial is done by comparing the intensive therapy and more intensive lipid-lowering therapy on Plaque regression that occurred in statin-naive patients with stable CAD.
Here the objective is to compare the treatment outcome between Intensive lipid-lowering therapy (Atorvastatin 40 mg) and more intensive lipid-lowering therapy (Rosuvastatin 40 mg + Ezetimibe 10 mg) which is conducted in stable CAD patients across multi-centres as randomised clinical trail.
A total of 104 patients were selected for the study. The enrollment of patients is done based on statin-naive patients with newly diagnosed stable CAD. The measures and diagnosis for treatment was done on Pre-specified Secondary endpoints that included change in total plaque value (TPV), non-calcified plaque volume (NCPV) and calcified plaque volume (CPV) across all coronary vessels at 9 and 18 months which are compared with baseline.
After FLOWPROMOTE Randomised clinical trail; the conclusion is that the greater regression of total and non-calcified coronary plaque burden is seen in more intensive lipid-lowering therapy when compared to intensive therapy. Here, the extent of plaque regression was related to achieved LDL-C levels, Supporting potential for partial reversal of coronary atherosclerosis with intensive lipid reduction.
Will you share your interest on this trail??
MBH/AS